Cut-off value for anti-Müllerian hormone in the diagnostic criteria for polycystic ovary syndrome in the Japanese population

被引:4
|
作者
Noguchi, Hiroki [1 ]
Iwasa, Takeshi [1 ]
Iwase, Akira [2 ]
Kanasaki, Haruhiko [3 ]
Kimura, Fuminori [4 ]
Kugu, Koji [5 ]
Saito, Kazuki [6 ]
Baba, Tsuyoshi [7 ]
Hara, Tetsuaki [8 ]
Matsuzaki, Toshiya [9 ]
机构
[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Obstet & Gynecol, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[2] Gunma Univ, Grad Sch Med, Dept Obstet & Gynecol, Gunma, Japan
[3] Shimane Univ, Fac Med, Obstet & Gynecol, Shimane, Japan
[4] Nara Med Univ, Dept Obstet & Gynecol, Nara, Japan
[5] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan
[6] Tokyo Med & Dent Univ, Grad Sch, Dept Perinatal & Maternal Med Ibaraki, Tokyo, Japan
[7] Sapporo Med Univ, Dept Obstet & Gynecol, Hokkaido, Japan
[8] Hiroshima Prefectural Hosp, Div Reprod Med, Hiroshima, Japan
[9] Yoshinogawa Med Ctr, Dept Obstet & Gynecol, Tokushima, Japan
关键词
anti-M & uuml; llerian hormone; antral follicle count; cut-off value; diagnostic criteria; polycystic ovary syndrome; ANTI-MULLERIAN HORMONE; ANTRAL FOLLICLE COUNT; INTEROBSERVER RELIABILITY; 3-DIMENSIONAL ULTRASOUND; MLLERIAN HORMONE; ANDROGEN EXCESS; WOMEN; PREVALENCE; OVULATION; AMH;
D O I
10.1111/jog.15972
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
AimTo establish cut-off values for anti-M & uuml;llerian hormone (AMH) and antral follicle count (AFC) in the diagnostic criteria for polycystic ovary syndrome (PCOS) applicable to the Japan Society of Obstetrics and Gynecology (JSOG) 2024 criteria and the Rotterdam/International Evidence-Based Guideline for the assessment and management of PCOS (IEBG) 2023 criteria based on a nationwide survey, respectively, taking into account age, assays, and structure of the diagnostic criteria.MethodsData were collected for 986 PCOS cases and 965 control cases using a national survey in Japan and used to establish cut-off values for AMH and AFC.ResultsSerum AMH levels were significantly higher in the PCOS group compared to the control group. Serum AMH showed a significant negative correlation with age and significant positive correlation with AFC in both groups. In multiple regression analysis, serum AMH level was independently affected by AFC and total testosterone. AMH cut-off values suitable for the JSOG 2024 criteria and the Rotterdam/IEBG 2023 criteria were separately established for the 20-29 and 30-39 years of age groups, respectively, and for Access, Lumipulse and Elecsys/ECLusys, respectively. AFC cut-off values suitable for the JSOG 2024 criteria and Rotterdam/IEBG 2023 criteria were also established separately. AFC exhibited statistically greater variability than AMH.ConclusionThe serum AMH level is the biochemical representation of ovarian findings in PCOS and considered objective and highly reliable. Therefore, it could serve as a surrogate for AFC as a marker of polycystic ovarian morphology in diagnostic criteria.
引用
收藏
页码:1368 / 1382
页数:15
相关论文
共 50 条
  • [31] Validation of an Anti-Müllerian Hormone Cutoff for Polycystic Ovarian Morphology in the Diagnosis of Polycystic Ovary Syndrome in the HARMONIA Study: Protocol for a Prospective, Noninterventional Study
    Piltonen, Terhi
    Allegranza, Deirdre
    Hund, Martin
    Buck, Katharina
    Sillman, Johanna
    Arffman, Riikka K.
    JMIR RESEARCH PROTOCOLS, 2024, 13
  • [32] Persistent Müllerian duct syndrome: A novel mutation in the Anti-Müllerian Hormone gene
    Ayça Altincik
    Fahri Karaca
    Hüseyin Onay
    Hormones, 2017, 16 : 205 - 208
  • [33] Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age
    Muhammad Salman Butt
    Javeria Saleem
    Sobia Aiman
    Rubeena Zakar
    Iftikhar Sadique
    Florian Fischer
    BMC Women's Health, 22
  • [34] Compatible cut-off values for luteinizing hormone and the luteinizing hormone/follicle-stimulating hormone ratio in diagnostic criteria of the Japan Society of Obstetrics and Gynecology for polycystic ovary syndrome
    Yanagihara, Rie
    Matsuzaki, Toshiya
    Aoki, Hidenori
    Tamura, Kou
    Nagashima, Mao
    Minato, Saki
    Kamada, Shuhei
    Yamamoto, Yuri
    Irahara, Minoru
    Iwasa, Takeshi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2023, 49 (01) : 253 - 264
  • [35] Evaluation of Biochemical Serum Markers for the Diagnosis of Polycystic Ovary Syndrome (PCOS) in Obese Women in Kazakhstan: Is Anti-Müllerian Hormone a Potential Marker?
    Madikyzy, Malika
    Durmanova, Aigul
    Trofimov, Alexander
    Akbay, Burkitkan
    Tokay, Tursonjan
    BIOMEDICINES, 2024, 12 (10)
  • [36] A novel mutation in the anti-müllerian hormone gene as cause of persistent müllerian duct syndrome
    Mariarosaria Lang-Muritano
    Anna Biason-Lauber
    Christopher Gitzelmann
    Corinne Belville
    Yves Picard
    Eugen J. Schoenle
    European Journal of Pediatrics, 2001, 160 : 652 - 654
  • [37] Relationship Between Anti-Müllerian Hormone (AMH) and Insulin Levels During Different Tanner Stages in Daughters of Women With Polycystic Ovary Syndrome
    Teresa Sir-Petermann
    Amanda Ladrón de Guevara
    Ethel Codner
    Jessica Preisler
    Nicolás Crisosto
    Bárbara Echiburú
    Manuel Maliqueo
    Fernando Sánchez
    Francisco Perez-Bravo
    Fernando Cassorla
    Reproductive Sciences, 2012, 19 : 383 - 390
  • [38] New additional biomarker proposal for the diagnosis of polycystic ovary syndrome through serum midkine cut-off value with anti-Mullerian hormone in Turkish population: A prospective study
    Erguven, M.
    Irez, T.
    Kahraman, S.
    Pirkevi, C.
    Dundar, G.
    Bilir, A.
    HUMAN REPRODUCTION, 2017, 32 : 452 - 452
  • [39] Elevated Anti-Müllerian Hormone Levels in Newborns of Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis Based on Observational Studies
    Siyu Zhou
    Danhua Lu
    Shu Wen
    Yongcheng Sheng
    Deying Kang
    Liangzhi Xu
    Reproductive Sciences, 2022, 29 : 301 - 311
  • [40] Age-specific reference values and cut-off points for anti-müllerian hormone in infertile women following a long agonist treatment protocol for IVF
    Z. Hiedar
    M. Bakhtiyari
    F. Foroozanfard
    M. Mirzamoradi
    Journal of Endocrinological Investigation, 2018, 41 : 773 - 780